ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials [PDF]
Clara Montagut, Joana Vidal
openalex +1 more source
ABSTRACT Cancer is a result of uncontrolled cell growth with the potential to damage or spread to another part of the body. It is the deadliest disease in the world; therefore, rapid and sensitive detection is essential to fight it. In the past few decades, many diagnosis tools have been developed to detect cancer and monitor therapy progress.
Md Mobarok Karim, Tahera Lasker
wiley +1 more source
Comment on: Exploring the utility of ctDNA testing in high-risk breast cancer patients in a community setting: case series. [PDF]
Narvaez D, Waisberg F.
europepmc +1 more source
Detection of ctDNA from dried blood spots after DNA size selection [PDF]
Katrin Heider +10 more
openalex +1 more source
Geographic and Socioeconomic Landscape of Veterans With Head and Neck Cancer
ABSTRACT Background US Veterans experience higher rates and worse outcomes for head and neck squamous cell carcinoma (HNSCC) compared to civilians. Geographic and socioeconomic barriers remain unclear. Methods This retrospective descriptive study analyzed VA data nationwide (2012–2022), identifying Veterans with HNSCC using ICD codes. Subsites included
Kristen L. Zayan +8 more
wiley +1 more source
Clinical Management of Circulating Tumor DNA in Breast Cancer: Detection, Prediction, and Monitoring. [PDF]
Lu Y, Ren L, Yang M, Liu J.
europepmc +1 more source
What's New? Circulating tumor cells can offer insights into treatment responses and metastatic recurrence, but current analysis methods are limited. Here, the authors tested a newly developed mass cytometry panel comprising biomarkers such as γH2AX and RAD51 in longitudinally monitored metastatic breast cancer patients.
Kathrin Niedermayer +17 more
wiley +1 more source
Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer. [PDF]
Ketch PW +15 more
europepmc +1 more source
Characteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatment [PDF]
Manouk K. Bos +5 more
openalex +1 more source

